- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Aegerion Pharmaceuticals Inc
+ Add to WatchlistAEGR:US
59.3700 USD 1.5900 2.61%As of 13:13:53 ET on 05/24/2013.
Snapshot for Aegerion Pharmaceuticals Inc (AEGR)
| Open: | 60.6100 | Day's Range: | 59.0900 - 61.3340 | Volume: | 187,067 |
|---|---|---|---|---|---|
| Previous Close: | 60.9600 | 52wk Range: | 12.8650 - 63.7200 | 1-Yr Rtn: | +337.83% |
Key Statistics for AEGR
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -2.7000 |
| Est. EPS (USD) (12/2013) | -2.2820 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 1,730.30 |
| Shares Outstanding (M) | 28.82 |
| 30 Day Average Volume | 748,195 |
| Price/Book (mrq) | 13.4935 |
| Price/Sale (ttm) | 1,366.6675 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/08/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for AEGR
Company Profile & Key Executives for AEGR
Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company researches small-molecule therapeutics for cardiovascular and metabolic desease. Aegerion's product candidates limit secretion of cholesterol and triglycerides.
| Marc C BeerChief Executive Officer | Mark J FitzpatrickChief Financial Officer |
| Mark SumerayChief Medical Officer | Martha J CarterChief Regulatory Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
AEGR News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page